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Open access undBackground: Changes in lung density on computed tomography (CT) are common after stereotactic abla-
tive radiotherapy (SABR) and can confound the early detection of recurrence. We performed a systematic
review to describe post-SABR ﬁndings on computed tomography (CT) and positron-emission tomography
(PET), identify imaging characteristics that predict recurrence and propose a follow-up imaging algo-
rithm.
Methods: A systematic review was conducted of studies providing detailed radiologic descriptions of ana-
tomic and metabolic lung changes after SABR. Our search returned 824 studies; 26 met our inclusion cri-
teria. Data are presented according to PRISMA guidelines.
Results: Acute changes post-SABR predominantly appear as consolidation or ground glass opacities. Late
changes often demonstrate a modiﬁed conventional pattern of ﬁbrosis, evolving beyond 2 years after
treatment. Several CT features, including an enlarging opacity, correlate with recurrence. Although PET
SUVmax may rise immediately post-SABR, an SUVmaxP 5 carries a high predictive value of recurrence.
Conclusions: CT density changes are common post-SABR. The available evidence suggests that recurrent
disease should be suspected if high-risk CT changes are seen with SUVmaxP 5 on PET. Further studies
are needed to validate the predictive values of such metrics, and for advanced analysis of CT changes
to allow early detection of potentially curable local recurrence.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 102 (2012) 335–342Stereotactic ablative radiotherapy (SABR), also known as stereo-
tactic body radiotherapy (SBRT), is now a standard treatment op-
tion for patients with stage I non-small cell lung cancer (NSCLC)
who are unﬁt for surgery or who are medically operable but refuse
surgery [1–3]. Image-guided SABR is characterized by large frac-
tion sizes coupled with accurate and precise delivery [4]. Although
data from randomized trials comparing SABR with surgery are not
available, non-randomized single-institution and population-
based studies have reported short/medium-term clinical outcomes
comparable to those of primary surgery, with reported local con-
trol rates of over 90% [2,5,6]. Comparable overall survival (OS) rates
in operable patients is also supported by a Markov model-based
decision analysis [7].
Radiation-induced CT lung changes after SABR differ from those
observed after conventionally fractionated radiotherapy. Lung
changes characteristic to conventional RT consist of CT changes
with straight borders corresponding to conventional treatmentl Cancer Program, 790 Com-
alma@uwo.ca (D.A. Palma).
er CC BY-NC-ND license.ﬁeld edges [8]. SABR employs complex beam arrangements to con-
form high-dose regions to the tumor and create steep dose gradi-
ents around the target volume, with a relatively large volume of
lung receiving low/intermediate doses (e.g. 5–40 Gy). In some in-
stances, CT changes after SABR can develop as mass-like patterns
that mimic the appearance of recurrent disease [9,10].
Although CT changes after SABR are common, and in-ﬁeld
recurrences are uncommon [11], distinguishing between the two
entities is of paramount importance in patients who may be candi-
dates for salvage therapy, including surgical resection [12]. Current
follow-up relies mainly on CT imaging, with positron emission
tomography (PET) or biopsy when recurrence is strongly sus-
pected. The drawback of over-investigation is unnecessary imaging
and the risks of invasive procedures [13,14], while under-investi-
gation of a growing recurrence risks missing the window of oppor-
tunity for salvage therapy. However the optimal imaging paradigm
after SABR is yet to be deﬁned.
As ﬁtter patients with longer life expectancies are now under-
going treatment with SABR, understanding long-term imaging
changes will take on increased importance, yet a standardized ap-
proach to follow-up and interpretation of imaging after SABR is
336 Detection of recurrence after lung SABRlacking. The goals of this study were to systematically review the
literature describing CT and PET ﬁndings following lung SABR, to
identify imaging characteristics that might predict for local recur-
rence, and to propose imaging guidelines based on the available
evidence for early detection of local recurrence after SABR.
Methods
A systematic review of the literature was performed according
to PRISMA guidelines [15]. We searched for English-language pa-
pers published between 1995 and June 2011 that met the follow-
ing criteria:
(1) Studies reporting on primary lung tumors, or tumors meta-
static to lung, treated with SABR.
(2) Studies providing a detailed radiologic description of benign
or malignant lung changes on follow-up CT or PET imaging.
The following exclusion criteria were used:
(1) Studies only reporting toxicity or tumor response but not
detailed radiologic changes.
(2) Case studies.
(3) Review articles.
Search strategy
Studies were identiﬁed by searching the MEDLINE (n = 439) and
EMBASE (n = 332) databases. These searches were completed in
June 2011. Search strategies are described in online Appendix e1
and selection process is illustrated in Fig. 1. After elimination of
duplicate papers, 439 pertinent papers were identiﬁed based on
their titles and abstracts. Of these, 43 were selected for detailed re-
view, and 22 ultimately met our inclusion criteria and were se-
lected for this review. 8729 conference abstracts from 2005 to
2011 were searched by textword: stereotactic, yielding 385 studiesFig. 1. Electronic sefor additional review. Of these, 10 were selected for detailed re-
view, one abstract was selected and its corresponding unpublished
manuscript was obtained from the author as a personal communi-
cation [16]. Finally, a review of reference lists of selected papers
yielded two additional abstracts of interest and both were selected
for the study. One abstract was obtained through expert sugges-
tion, and was included in this review. A total of 23 articles and
three abstracts were reviewed, summarized in online Appendix
e2 and e3.
Results
Acute and late CT lung changes post-SABR
The pattern of changes in lung parenchyma on CT post-SABR
has been described in several studies (Table 1 and Appendix e4)
[9,17–22] and can generally be categorized as acute (within
6 months, corresponding to pneumonitis) or late (after 6 months,
corresponding to ﬁbrosis) [18,23].
Several papers have classiﬁed acute changes into one of ﬁve
general patterns: diffuse consolidation, patchy consolidation,
diffuse ground-glass opacities (GGO), patchy GGO, and no change
(Table 1) [9,17–19]. Representative images showing each of these
changes are well illustrated in reference [9]. These classiﬁcations
are based on descriptions of changes after conventional radiother-
apy [24,25]. Based on weighted averages across studies, the overall
incidences of increased CT density in the acute setting was 62%, the
majority of which is consolidation (45% of patients), with GGO less
common. Dahele et al. analyzed the temporal pattern of CT changes
and found that the actuarial median time to acute CT change was
17 weeks [9].
Late changes include modiﬁed conventional (consolidation, vol-
ume loss, and bronchiectasis similar to but less extensive than con-
ventional radiation ﬁbrosis), scar-like ﬁbrosis (linear opacity in the
region of the original tumor), mass-like ﬁbrosis and no change,
again illustrated in the study by Dahele et al. [9]. The termsarch strategy.
Table 1
Incidence and patterns of CT lung changes with SABR.
Study Benign acute CT changes (%) Benign late CT changes (%) Recurrence features
Diffuse
consolidation
Patchy
consolidation
Diffuse
GGO
Patchy
GGO
No
evidence
of
increasing
density
Modiﬁed
conventional
Scar-
like
ﬁbrosis
Mass-
like
ﬁbrosis
No
evidence
of
increasing
density
Dahele
et al.
[9]
Acute
n = 67
lesions
16 24 7 6 46 71 11 7 11 Recurrences excluded
from study
Late n = 68
lesions
Kimura
et al.
[17]
n = 52
lesions
38 15 12 2 33 62 22 17 0 Four based on CT
enlargement, evolved
from scar-like (n = 2)
and mass-like (n = 2)
ﬁbrosis
Palma
et al.
[18]
3DCRT
n = 50
patients
14 22 4 16 44 Excluded from study
RA n = 25
patients
32 8 4 16 40
Trovo
et al.
[19]
6 months
n = 33
patients
27 33 12 6 21 46 14 20 20 Three based on CT
enlargement and
increased SUV,
evolved from diffuse
GGO (n = 1) patchy
consolidation and GGO
(n = 2)
12 months
n = 35
patients
Weighted Acute
n = 227
24 21 8 8 38 62 15 14 9
Averages Late
n = 155
Abbreviations: computed tomography (CT), stereotactic ablative radiotherapy (SABR), ground glass opacity (GGO), three-dimensional conformal radiotherapy (3DCRT), Rapid-
Arc (RA).
Table 2
Summary of malignant CT lung changes with SABR.
Study n
recurrence/
total
Distinguishing features of recurrence
Kato et al.
[31]
5/27  Bulging margin 80% (versus 5%)
 Linear margin disappearance 100% (versus
9%)
 Air bronchogram disappearance 100% (ver-
sus 19%)
 Ipsilateral pleural effusion 100% (versus 23%)
 Opacity increased in size after 12 months
 Lymph node enlargement 60% (versus 18%)
 Inhomogeneous enhancement 100% (versus
67%)
Matsuo
et al.
[26]
3/27 mass-
like lesions
 Difference in size after 12 months was the
only statistically signiﬁcant predictor of
recurrence (p < 0.01)
Takeda
et al.
[10]
3/50 Initial regrowth with recurrence n = 3 (2
pathology proven)
 At 5.9, 9.2, and 12.0 months; shape: solid
n = 3
K. Huang et al. / Radiotherapy and Oncology 102 (2012) 335–342 337‘‘diffuse’’ versus ‘‘patchy’’ have also been objectively deﬁned
according to size criteria and severity [18]. Across studies, the
mean incidence of all CT lung changes was 91% of cases. The pre-
dominant CT density patterns were modiﬁed conventional
(62%) and less commonly scar-like (15%) and mass-like ﬁbrosis
(14%). The appearance of mass-like ﬁbrosis appears to peak at 1
to 2 years post-SABR [9]. A study by Matsuo et al. analyzed only
mass-like consolidation and noted its appearance in 68% of cases,
at a median of 5 months post-SABR [26].
Other classiﬁcation schemes for CT patterns have also been re-
ported (Appendix e4) [20–22]. The incidence of early and late radi-
ation-induced lung changes ranged from 54–79% to 80–100%,
respectively.
Although early ﬁndings of severe radiation pneumonitis (RP)
are predictive of late changes [9] they are not a pre-requisite
[10]. Acute and late CT changes have also been correlated with
dose and volume as summarized in Appendix e5 [20,27–30]. The
graphical RP is generally correlated with doses above 20 Gray [29].Initial regrowth without recurrence n = 14 (4
pathology proven)
 Median time 21.4 months (8.6–35.6); shape:
solid n = 9
Abbreviations: computed tomography (CT), stereotactic ablative radiotherapy
(SABR).Post-SABR CT ﬁndings suggestive of recurrence
Three studies directly analyzed the radiological appearance of
recurrent disease in the post-SABR setting [10,26,31]. A summary
of post-SABR imaging characteristics of recurrent disease is pre-
sented in Table 2. The presence of an enlarging mass as a sign of
recurrence is supported by all three studies. According to Kato
et al., the most reliable indicator of local recurrence is increased
size of the opacity after 12 months and additional CT ﬁndings sug-
gestive of recurrence include a bulging margin, disappearance of
air bronchograms and appearance of pleural effusion [31]. Of these,
disappearance of air bronchograms and emergence of pleural effu-sion tended to appear early (within 12 months) and has been sug-
gested as an aid to the early detection of recurrence. Matsuo et al.
similarly found a correlation between an increase in size after
12 months and recurrence (p < 0.01). They found that recurrence
was not predicted by the initial timing of the abnormality, confor-
mity of the abnormality to dose distribution or the presence of ec-
338 Detection of recurrence after lung SABRtatic (distended/dilated) bronchi, some of which had been previ-
ously found to be suggestive of recurrence after conventional RT
[26]. An enlarging mass may be sensitive, but not speciﬁc for recur-
rence as Takeda et al. report that the diagnosis of only a minority of
patients with an enlarging mass was ultimately recurrence, based
upon biopsy and further imaging studies [10].Expected metabolic ﬁndings on post-SABR PET
The role of 2-ﬂuoro-2-deoxy-D-glucose (FDG)-PET in staging
and evaluation of treatment response after conventional radiother-
apy treatment is well understood [32]. An increase in standardized
uptake value (SUV) is normally a sign of increased metabolic activ-
ity of tumor cells, which is a marker for tumor recurrence. How-
ever, in the post SABR setting, FDG avidity can also be related to
normal acute radiation inﬂammatory response of lung tumors/
parenchyma [33].Table 3
Selected studies reporting on metabolic ﬁndings after SABR on FDG-PET.
Study Whole cohort
Bollineni et al.
[44]
n = 132  Median SUVmax 3.0
Chang et al. [16,
and
unpublished
manuscript]
n = 128
Coon et al. [34] n = 28  Median SUVmax 1.7
Dahele et al. [35] n = 31  Median SUVmax: 1.7 (up to 4.8)
 Median reductions SUVmax: 3.6 or 64%
Feigenberg et al.
[39]
n = 18  Mean SUVmax was 2.6 (max 7.0)
 13 of 15 with drop in SUVmax
 Drop in the SUVmax by 3 months corre
control
Abstract
Fuss et al. [40] n = 30  SUV declined to < 3.0 at 12 weeks in all 28
recurrenceAbstract
Henderson et al.
[36]
n = 14  Median SUVmax 6.04 at 2 weeks, 2.80 at 6
12 months
 6 of 13 patients had SUVmax > 3.5 at 12 mo
free
Pilot study
Hoopes et al. [33] n = 28 (subset
n = 4 with
delayed PET)
 Median SUV = 4.2. In subset with delayed
bolic activity (SUV 2.5–5.87) may exist
26 months) following SABR without recurre
Matsuo et al. [37] n = 23  SUVmax post-SABR signiﬁcantly higher at <
SUVmax 4.9) than 6–12 months (2.6), 12–
or > 24 months (2.3)
Mohammed et al.
[38]
n = 39  Rapid reduction in mean SUVmax to 3.4 a
16 weeks, and 3.7 at 52 weeks
 Beyond 6 weeks, inﬂammatory changes are
residual activity that persists over 1 year
Takeda et al. [10] n = 4  3 patients without recurrence had SUVmax
Vahdat et al. [41] n = 20  Mean SUVmax of 2.3(up to 5.7) as early
peaked prior to 18–24 months and returned
levels’’ with mean SUVmax 2.0(up to 2.8) a
 Transient elevations seen as radiation pneu
Abbreviations: stereotactic ablative radiotherapy (SABR), 18F-ﬂuorodeoxyglucose positron
values (SUV).Several studies report normal tumor response values after SABR
either as stable SUV or as a decline to background SUV [33–40].
Transient rises can occur within the ﬁrst 6 months after SABR,
but usually not over an SUVmax of 5, consistent with acute post-
radiation normal tumor/tissue response (Table 3) [33,36,41,42].
Henderson et al. noted a trend in the expected SUVs post-SABR; tu-
mors with low pre-SABR SUVs were correlated with transient rises
at 2 weeks post-SABR, whereas high pre-SABR SUVs were corre-
lated with a post-SABR SUV decline at 2 weeks [36].Post-SABR metabolic ﬁndings of recurrence
FDG-PET is commonly considered when local recurrence is sus-
pected on CT imaging [36]. However, the use of PET in the evalua-
tion of treatment response and detection of tumor recurrence after
SABR is controversial. Some authors have suggested that metabolic
changes on PET may provide an earlier indicator of tumor recur-Recurrence/treatment failure features
n = 6  SUVmax 5.0 at 3 months as cut-off: 2 year
local control for high and low SUVmax groups
were 78.8% versus 97.1% (p = 0.001)
 SUVmax > 5.0: better predictor for local con-
trol than lesion size (p = 0.025)
n = 8  SUVmax at 3–6 months > 5.0 predictive of
recurrence:
Positive predictive value = 83%
Negative predictive value = 75%
 High SUVmax at 9 months signiﬁcantly pre-
dictive of failure
n = 2  Initial SUVmax decrease of 0.4% then local
progression (not deﬁned)
n = 1  Progressive disease at 7 month
 Initial complete anatomic and metabolic
response at 3 month
lated with local
n = 3  SUV was stable or increased
 3 recurrences of 5 patients with stable or
increase in SUVmax at 9–12 months
 1 recurrence of 4 patients with SUVmax > 2.5
at 3 months
patients without n = 2  SUV failed to decline at 12 weeks
 Failure to decline <3.0 may indicate resis-
tance to therapy
months, 3.58 at
nths recurrence
n = 0
PET, hypermeta-
for years (22–
nce
n = 0
6 months (mean
24 months (3.0),
Excluded
t 6 weeks, 3.0 at
evident as low
n = 0
< 5.0 n = 1  SUVmax 5.0
as 3 month, all
to ‘‘background
t 18–24 months
monitis on CT
n = 1  SUVmax of 8.4 at 24 months
 Corresponding benign CT changes
emission tomography (FDG-PET), computed tomography (CT), standardized uptake
Fig. 2. Proposed algorithm for follow-up of patients post-SABR who are candidates
for salvage treatment. ⁄Enlargement of CT density: as described by RECIST 1.1 by an
increase in the sum of the diameters (SOD) of the target lesion by at least 20% from
baseline (i.e. post-SABR nadir size) and absolute increase in SOD of at least 5 mm
[44]. High-risk features: sequential enlargement on repeat CT, opacity enlargement
after 12 months, bulging margin, disappearance of air bronchograms, linear margin
disappearance, ipsilateral pleural effusion or lymph node enlargement. Abbrevia-
tions: Stereotactic ablative radiotherapy (SABR), computed tomography (CT), 18F-
ﬂuorodeoxyglucose positron emission tomography (FDG-PET), standardized uptake
values (SUV).
K. Huang et al. / Radiotherapy and Oncology 102 (2012) 335–342 339rence than tumor size on CT, even arguing for routine PET follow-
up imaging and prompting a pilot study on routine PET imaging
post-SABR [36], which remains investigational at present. PET
may incorrectly identify patients at risk for recurrence, subjecting
patients to the unnecessary risk of biopsy [14]. The limited avail-
ability of PET imaging in many centers further restricts its use in
clinical practice.
Due to the low incidence of local recurrences, studies examining
their metabolic response signature are limited. A selected summary
of FDG-PET values associated with both tumor response and local
failure is provided in Table 3. The total number of local recurrences
in these 12 PET reports is very small (n = 24), follow-up is heteroge-
nous, and the PET imaging strategies vary. Acknowledging this, the
following preliminary observations are made: (i) SUVmax associ-
ated with recurrence may fail to decline or it increases over time,
sometimes after an initial fall [34,35,39,40], (ii) if a PET scan is done
on CT suspicion of recurrence then an SUVmax of 5 ormore has gen-
erallybeen reportedas indicativeof recurrence, and if thescan isper-
formed 3–6 months after SABR in an attempt to predict response,
then an SUVmax of 5 ormore has also been associated with a higher
risk of recurrence [10,16,41,43], (iii) transient ﬂuctuations in SUV-
max have been reported, for example, recurrences may exhibit a
transient initial SUV decrease [34,35], perhaps as the effects of acute
radiationpneumonitis resolve before increasedmetabolic activity of
tumor cells is detected. A transient decrease and subsequent in-
crease in SUV has also been associated with apparent infection
rather than recurrence [36].
Only one study examined the positive predictive values (PPV)
and negative predictive values (NPV) of a PET SUVmax cutoff for
discriminating recurrence from post-SABR changes. Data from
Chang et al. use a cutoff of SUVmax = 5 on FDG PET approximately
3–6 months post-SABR for predicting recurrence, ﬁnding a PPV of
83% and a NPV of 75% after a median follow-up of 31 months. In
addition, SUVmax at 9 months was also correlated with develop-
ment of recurrence ([16] and associated unpublished manuscript).
A separate study, presented only in abstract form, used an SUVmax
cut-off of 5.0 at 3 months post-SABR and found improved local
control with the SUVmax < 5 group (97.1% if SUVmax 6 5, vs.
78.8% if SUVmax > 5, p = 0.001) at 2 years, with a trend toward
improved OS [43]. The performance of FDG-PET in these circum-
stances may change as the follow-up duration increases.
The limited data available suggest that 3–9–months post-SABR
acute radiation changes may be resolving, allowing the metabolic
activity of recurrent tumors to be more reliably detected, and that
an SUVmax threshold of 5 at 3–6 months post-SABR may serve as a
useful cut-off value for identifying lesions at high risk of subse-
quent local failure. This may not apply equally to lesions that were
initially PET negative or weakly FDG-avid nor should PET ﬁndings
be interpreted in isolation.Recommendations for follow-up imaging
Based on the above ﬁndings, a proposed algorithm for imaging
follow-upof SABRpatientswhoare candidates for salvage treatment
is shown in Fig. 2. The primary imaging modality is CT thorax with
contrast. In the absence of data, a frequency of 3–6 months is sug-
gested, at least for the ﬁrst year, thereafter the frequency might be
tailored to whether the patient is medically operable (e.g. 6–12 m,
depending on time frame), or not (e.g. annually), and the suspicion
of recurrence (increased frequency if recurrence is a possibility).
FDG-PET is indicated when recurrence is suspected on CT imag-
ing as demonstrated by an enlarging mass with 20% increase in
sum of diameters (SOD) and absolute increase in SOD of at least
5 mm from baseline measurements post-SABR, based on RECIST
1.1 criteria [44], with or without the presence of other high-risk
features on CT. These include sequentially enlarging mass-like le-sion, opacity enlargement after 12 months, bulging margin, disap-
pearance of air bronchograms, linear margin disappearance,
ipsilateral pleural effusion, or lymph node enlargement.
When FDG-PET imaging is obtained, it should be performed
preferably on the same machine or on a standardized machine,
and residual increases in SUV even 1 year after SABR should not
automatically be deﬁned as a recurrence. The use of routine PET/
CT at a predeﬁned time point is still subject to investigation and,
although useful in the setting of prospective clinical trials, cannot
be recommended for routine follow-up at this time without cur-
rent evidence to support it, particularly given very low rates of lo-
cal recurrence, the limited availability of FDG-PET in many centers,
and the high costs involved. Biopsy or resection should be consid-
ered on a case by case basis, taking into consideration the safety,
availability of salvage options and the clinical suspicion for
recurrence.
The limited evidence suggests that when SUVmax equals 5 or
greater, recurrence should be highly suspected, and a biopsy or
resection should be considered if safe. Some patients may have
340 Detection of recurrence after lung SABRrecurrences that are not FDG avid, this is a particular concern if the
original primary had a low SUV, and therefore in patients with
SUVmax < 5 who have suspicious CT ﬁndings, biopsy should still
be considered.
Operable patients can be considered for surgical salvage options
whereas non-surgical salvage options can be considered in medi-
cally inoperable patients, preferably in prospective study protocols
and with appropriate counseling for the expected increase in risk
of severe toxicity. Outcomes from repeated use of SABR for in-ﬁeld
salvage have not been reported, however SABR has been used in
patients who have previously received fractionated radiotherapy
to the chest, with higher risks of toxicity [45].Discussion
CT density changes are common post-SABR, yet high-level evi-
dence to guide discrimination between recurrence and ﬁbrosis is
lacking. This is particularly important in patients who are candi-
dates for salvage therapy in whom the inability to distinguish these
scenarios is especially concerning. Benign CT lung changes follow
common acute and late patterns, appearing predominantly as con-
solidation within the ﬁrst 6 months after treatment, with a modi-
ﬁed conventional pattern of ﬁbrosis emerging 6 months to years
after treatment. An enlarging CT opacity after SABR is the most fre-
quently reported feature of recurrence. Although PET SUVmax may
transiently rise immediately post-SABR and persist for over
12 months without recurrence, SUVmaxP 5 may serve as a useful
cutoff for recurrence.
Advances in the ﬁeld of SABR and CT/PET imaging in lung cancer
continues to emerge [46,47]. The issue of discriminating between
benign ﬁbrosis and recurrence is expected to take on increasing
clinical importance in the coming years. Radiographic changes
post-SABR will be encountered more frequently as the use of SABR
for the treatment of early stage NSCLC increases, as the use of
screening CT increases the detection of early stage disease, and
as ﬁtter patients with longer life expectancies are treated. The early
detection of recurrence is especially important in the medically
operable patient population or patients for whom curative surgical
salvage treatments are still available. This study is the ﬁrst, to our
knowledge, to systematically review the literature on the discrim-
inative value of imaging and provide structured recommendations
based on the available evidence. The fact that these appear to re-
ﬂect contemporary clinical practice is encouraging, however they
also point to deﬁciencies in the current evidence base. Our algo-
rithm improves upon one presented previously by RTOG 0618, by
providing more high-risk features on CT and including speciﬁc
SUVmax cutoffs, again based on a systematic review of the litera-
ture [48].
A standardized deﬁnition of recurrence becomes especially
important when comparing results across studies. Several Radia-
tion Therapy Oncology Group (RTOG) clinical trials (0813, 0915,
0236, 0618) deﬁne local recurrence as an increase in tumor size
as noted on CT imaging, along with either increased SUV on FDG-
PET to original baseline levels, or biopsy proof of disease [48]. Rec-
ognizing the inability to obtain biopsy proof in all patients, the
available evidence currently supports a deﬁnition of a recurrence
as meeting either of two criteria: (1) increase in tumor size on
CT imaging with SUVmax P5, or (2) pathology-proven disease.
Where clinically appropriate, radiological ﬁndings should be con-
ﬁrmed pathologically with biopsy and/or resection. The presence
of any malignant cells on biopsy should indicate recurrence,
regardless of their viability, since assessment of viability after SABR
has not been validated.
Although historical studies have reported lung changes after
conventionally fractionated radiotherapy or chemoradiotherapy[8], which tend to be less conformal than that of SABR, to our
knowledge no study has rigorously scored morphological changes
for direct comparison across these treatment modalities. Limited
conclusions can be drawn from two similar studies that measured
hounsﬁeld unit (HU) density changes after either SABR [49] or che-
moradiotherapy [50], whereby the HU changes observed after
SABR appear larger at each dose level. A current study is underway
using HU density changes pooled from several centers, including
patients treated with SABR, radiotherapy alone, and chemoradio-
therapy, however the results will not be available for several
months.
The conclusions of this study must be considered in the context
of its strengths and limitations. Large studies examining this ques-
tion are lacking, and studies vary in their patient selection, radio-
therapy doses, follow-up regimens, and CT reporting criteria.
Biopsy proof of recurrence was not obtained in the vast majority
of patients, and deﬁnitions of recurrence varied between studies.
SUV readings from FDG-PET scans can vary between institutions
using different protocols and can ﬂuctuate due to differences in
blood glucose levels and PET agents used [35,42]. The individual
studies reported here were mainly retrospective, and independent
validation of many predictive factors is lacking.
There are limitations inherent in our follow-up imaging recom-
mendations, as they are based on data detailing only 35 total local/
in-ﬁeld recurrences as seen on CT or PET. The most reliable indica-
tor for recurrence is an enlarging mass, and additional high-risk
features based on results of a single study were also included in
our algorithm to help guide treatment and would require further
validation. We acknowledge that our post-SABR SUVmax recom-
mendations are based on SUVs gathered from both routine and
non-routine PET/CT data, however we feel these results can be
extrapolated to the setting of PET/CT at time of suspected
recurrence. To validate and reﬁne these recommendations, more
studies are needed. Although the evidence is imperfect, the
algorithm presented provides a framework that can be tested
prospectively and modiﬁed in the future, and may assist clinicians
who are currently following SABR patients, until further data
becomes available.
Future directions include the objective quantiﬁcation of CT
changes; studies examining CT density, CT-based volumetric
assessment and other quantiﬁcation methods are emerging [49].
Additional imaging studies with larger sample sizes and longer fol-
low-up times are needed to detect the number of recurrences re-
quired to draw more robust conclusions. A notable challenge in
comparing sequential CT chest images after SABR may be lung vol-
ume retraction due to lung ﬁbrosis, however this may be amenable
to deformable image registration, another potential area of future
study [49,51]. Further characterization of expected SUV ﬂuctua-
tions with time may also help to distinguish abnormal SUV rises
that may be correlated with recurrence. Recent data suggests
pre-treatment SUVmax P6 signiﬁcantly predicts local recurrence
after SABR [47], and one may argue for tailored follow-up sched-
ules for such higher risk patients, a concept that requires valida-
tion. Future studies should also present receiver-operator
characteristic curves and standard metrics such as sensitivity and
speciﬁcity. These data will allow for a reﬁnement of the prelimin-
ary management algorithm presented herein.
In conclusion, as SABR becomes more widely used in clinical
practice, the detection of local recurrence during follow-up be-
comes increasingly important. This systematic review suggests
that post-SABR lung changes demonstrate common acute and late
patterns on CT. Furthermore, although the available evidence is
limited, recurrence after SABR generally correlates with sequential
opacity enlargement on follow-up CT imaging and SUV of P5.
More studies, including those rigorously analyzing CT and PET cut-
offs for prediction of recurrence are urgently needed to facilitate
K. Huang et al. / Radiotherapy and Oncology 102 (2012) 335–342 341early detection of potentially treatable recurrence while prevent-
ing unnecessary invasive interventions for benign disease.Conﬂict of interest
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